Roche Holding AG (OTCMKTS:RHHBY) Receives Average Rating of “Hold” from Brokerages

Roche Holding AG (OTCMKTS:RHHBY) has been given an average rating of “Hold” by the eleven ratings firms that are currently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $51.50.

RHHBY has been the subject of a number of recent analyst reports. Argus raised Roche from a “hold” rating to a “buy” rating in a research report on Monday, April 6th. Morgan Stanley upgraded Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 price target for the company in a research note on Friday, April 24th.

Roche Price Performance

OTCMKTS RHHBY opened at $53.04 on Friday. The firm’s fifty day simple moving average is $51.29 and its two-hundred day simple moving average is $52.68. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72. Roche has a 12-month low of $37.51 and a 12-month high of $60.85.

Institutional Trading of Roche

Institutional investors have recently bought and sold shares of the stock. Curio Wealth LLC purchased a new stake in Roche during the 3rd quarter worth approximately $25,000. McIlrath & Eck LLC purchased a new position in shares of Roche in the first quarter worth $39,000. Oakworth Capital Inc. lifted its stake in shares of Roche by 20.8% during the fourth quarter. Oakworth Capital Inc. now owns 1,658 shares of the company’s stock worth $86,000 after buying an additional 285 shares during the period. Atlas Capital Advisors Inc. acquired a new stake in shares of Roche during the fourth quarter worth $192,000. Finally, Douglass Winthrop Advisors LLC purchased a new stake in shares of Roche during the third quarter valued at $201,000.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.